Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses the TOURMALINE-MM4 study (NCT02312258), a Phase III trial of oral ixazomib maintenance therapy in participants with newly-diagnosed, transplant ineligible multiple myeloma, presented at EHA 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).